Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 9/20 | 0.45 |
| ▸ | MAOB | P27338 | 9/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517557 | 1.00 | MCL1 (0.50) | MCL1MAOAMAOBACHEGRIN1 | |
| SCHEMBL17102962 | 1.00 | MCL1 (0.50) | MCL1MAOAMAOBACHEGRIN1 | |
| SCHEMBL17517525 | 0.96 | MCL1 (0.51) | MCL1MAOAMAOBACHE | |
| SCHEMBL20340619 | 0.93 | MCL1 (0.53) | MCL1MAOAMAOB | |
| SCHEMBL28805496 | 0.91 | MCL1 (0.47) | MCL1MAOAMAOB | |
| SCHEMBL27899824 | 0.85 | MCL1 (0.67) | MCL1 | |
| SCHEMBL17517527 | 0.81 | CCNB2 (0.54) | MCL1MAOAMAOB | |
| SCHEMBL17102964 | 0.81 | CCNB2 (0.54) | MCL1MAOAMAOB | |
| SCHEMBL17102958 | 0.81 | CCNB2 (0.54) | MCL1MAOAMAOB | |
| SCHEMBL17122538 | 0.81 | ALKBH5 (0.44) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
| EP-2924042-A1 | BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2015-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BRCA1, CA7, DCK | MCL1 205/4885MAOA 3499/4885MAOB 1253/4885 |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | MCL1 209/4885MAOA 3791/4885MAOB 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.